Literature DB >> 30221066

Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities.

Camille Jacqueline1,2, Nathalie Bonnefoy3, Guillaume M Charrière4, Frédéric Thomas1,2, Benjamin Roche1,5,6.   

Abstract

The recent breakthroughs in the understanding of tumor immune biology have given rise to a new generation of immunotherapies, harnessing the immune system to eliminate tumors. As the typology and frequency of encountered infections are susceptible to shape the immune system, it could also impact the efficiency of immunotherapy. In this review, we report evidences for an indirect link between personal history of infection and different strategies of immunotherapy. In the current context of interest rise for personalized medicine, we discuss the potential medical applications of considering personal history of infection to design immunotherapeutic strategies.

Entities:  

Keywords:  Adoptive cell transfer; Cancer vaccine; Immune checkpoints; Immunotherapy; Infections; Personalized medicine

Year:  2018        PMID： 30221066      PMCID： PMC6136881          DOI： 10.1080/2162402X.2018.1466019

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  95 in total

Review 1.  VZV T cell-mediated immunity.

Authors:  Adriana Weinberg; Myron J Levin
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.

Authors:  Hso-Chi Chaung
Journal:  Int Immunopharmacol       Date:  2006-06-28       Impact factor: 4.932

3.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

4.  PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

Authors:  Laetitia They; Henri-Alexandre Michaud; Ondine Becquart; Virginie Lafont; Bernard Guillot; Florence Boissière-Michot; Marta Jarlier; Caroline Mollevi; Jean-François Eliaou; Nathalie Bonnefoy; Laurent Gros
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Antitumor activity of dual-specific T cells and influenza virus.

Authors:  A Murphy; J A Westwood; L E Brown; M W L Teng; M Moeller; Y Xu; M J Smyth; P Hwu; P K Darcy; M H Kershaw
Journal:  Cancer Gene Ther       Date:  2007-03-02       Impact factor: 5.987

7.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

8.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 9.  Acute infections as a means of cancer prevention: opposing effects to chronic infections?

Authors:  Stephen A Hoption Cann; J P van Netten; C van Netten
Journal:  Cancer Detect Prev       Date:  2006-02-21

10.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113
View more
  2 in total

1.  Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.

Authors:  Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2020-05-28       Impact factor: 11.151

2.  Is adaptive therapy natural?

Authors:  Frédéric Thomas; Emmanuel Donnadieu; Guillaume M Charriere; Camille Jacqueline; Aurélie Tasiemski; Pascal Pujol; François Renaud; Benjamin Roche; Rodrigo Hamede; Joel Brown; Robert Gatenby; Beata Ujvari
Journal:  PLoS Biol       Date:  2018-10-02       Impact factor: 8.029
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.